Literature DB >> 15688035

Cell-type-specific regulation of distinct sets of gene targets by Pax3 and Pax3/FKHR.

Salma Begum1, Nashmil Emami, Nashmil Emani, Albert Cheung, Olivia Wilkins, Sandy Der, Paul A Hamel.   

Abstract

The oncogenic fusion protein, Pax3/FKHR, is a more potent transcription factor relative to its normal counterpart, Pax3. Since Pax3 induced a mesenchymal to epithelial transition (MET) in human SaOS-2 osteosarcomas, we hypothesized that Pax3/FKHR would also induce a morphological change in SaOS-2 cells. We demonstrate here that Pax3/FKHR more potently induces a MET in SaOS-2 cells than Pax3. This greater potency was further evident where Pax3/FKHR, but not Pax3, induced a morphological alteration in U2-OS osteosarcoma cells. By microarray analysis, we determined that Pax3/FKHR altered the expression of gene targets in a manner quantitatively and qualitatively distinct from Pax3. Three classes of genes were identified: (i) genes induced or repressed by Pax3 and Pax3/FKHR, (ii) genes induced or repressed by Pax3/FKHR but not Pax3 and (iii) genes induced by Pax3/FKHR but repressed by Pax3. Chromatin immunoprecipitations confirmed the direct binding of Pax3/FKHR to the promoter region of several factors including cannabinoid receptor-1, EPHA2 and EPHA4. Verification of the microarray data also revealed coordinate alteration in the expression of factors involved in BMP4 signalling. Regulation of gene expression by Pax3 and Pax3/FKHR is, however, cell-type specific. BMP4 expression, for example, was repressed by both Pax3 and Pax3/FKHR in SaOS-2 cells, while in the rhabdomyosarcoma, RD, Pax3/FKHR, but not Pax3, induced BMP4 expression. Thus, our data reveal that Pax3/FKHR regulates a distinct but overlapping set of genes relative to Pax3 and that the global set of Pax3 and Pax3/FKHR gene targets is cell-type specific.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15688035     DOI: 10.1038/sj.onc.1208315

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

1.  Comparative analysis of paired- and homeodomain-specific roles in PAX3-FKHR oncogenesis.

Authors:  Youbin Zhang; Joel Schwartz; Chiayeng Wang
Journal:  Int J Clin Exp Pathol       Date:  2008-12-01

2.  PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.

Authors:  Berkley E Gryder; Marielle E Yohe; Hsien-Chao Chou; Xiaohu Zhang; Joana Marques; Marco Wachtel; Beat Schaefer; Nirmalya Sen; Young Song; Alberto Gualtieri; Silvia Pomella; Rossella Rota; Abigail Cleveland; Xinyu Wen; Sivasish Sindiri; Jun S Wei; Frederic G Barr; Sudipto Das; Thorkell Andresson; Rajarshi Guha; Madhu Lal-Nag; Marc Ferrer; Jack F Shern; Keji Zhao; Craig J Thomas; Javed Khan
Journal:  Cancer Discov       Date:  2017-04-26       Impact factor: 39.397

3.  Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group.

Authors:  Pooja Hingorani; Edoardo Missiaglia; Janet Shipley; James R Anderson; Timothy J Triche; Mauro Delorenzi; Julie Gastier-Foster; Michele Wing; Douglas S Hawkins; Stephen X Skapek
Journal:  Clin Cancer Res       Date:  2015-10-15       Impact factor: 12.531

Review 4.  Cannabinoids, endocannabinoids, and cancer.

Authors:  Daniel J Hermanson; Lawrence J Marnett
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 5.  Childhood rhabdomyosarcoma: recent advances and prospective views.

Authors:  C Wang
Journal:  J Dent Res       Date:  2011-09-13       Impact factor: 6.116

6.  Identification of a new class of PAX3-FKHR target promoters: a role of the Pax3 paired box DNA binding domain.

Authors:  L Zhang; C Wang
Journal:  Oncogene       Date:  2006-09-11       Impact factor: 9.867

7.  Nephroblastoma overexpressed (NOV/CCN3) gene: a paired-domain-specific PAX3-FKHR transcription target that promotes survival and motility in alveolar rhabdomyosarcoma cells.

Authors:  Y Zhang; C Wang
Journal:  Oncogene       Date:  2011-03-21       Impact factor: 9.867

Review 8.  PAX3-FOXO1 fusion gene in rhabdomyosarcoma.

Authors:  Corinne M Linardic
Journal:  Cancer Lett       Date:  2008-05-23       Impact factor: 8.679

9.  Constitutively active Akt induces ectodermal defects and impaired bone morphogenetic protein signaling.

Authors:  Carmen Segrelles; Marta Moral; Corina Lorz; Mirentxu Santos; Jerry Lu; José Luis Cascallana; M Fernanda Lara; Steve Carbajal; Ana Belén Martínez-Cruz; Ramón García-Escudero; Linda Beltran; José C Segovia; Ana Bravo; John DiGiovanni; Jesús M Paramio
Journal:  Mol Biol Cell       Date:  2007-10-24       Impact factor: 4.138

10.  Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma.

Authors:  Mathivanan Jothi; Munmun Mal; Charles Keller; Asoke K Mal
Journal:  Mol Cancer Ther       Date:  2013-10-09       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.